Background: The study was conducted to assess the efficacy of MTX and MTX+SSZ combination in early RA with low & moderate disease activity, in absence of PPF, in terms of Disease Activity Score, to review the validity of ACR 2012 recommendation, in eastern Indian population region.
Methods: Patients with early RA with low & moderate disease activity without PPF in eastern Indian population region were allocated into mono and dual DMARD groups. Efficacy evaluated by DAS 28, CDAI, SDAI, HAQ score between two groups at 12 wks and 24 wks.
Results: The study showed no statistically significant difference of Disease Activity scores in between two groups evaluated at 12 weeks and 24 weeks. But there was significant difference in Disease activity scores in 12 weeks and 24 weeks in comparison to 0 week value in both the groups.
Conclusions: In patients with early RA with low to moderate disease activity without PPF, dual therapy is equally effective as compared to mono therapy.